CY1109447T1 - Πολυμορφικες μορφες της υδροχλωρικης 1-[4-(5-κυανοϊνδολ-3-υλ) βουτυλ]-4-(2-καρβαμοϋλβενζοφουραν-5-υλ)πιπεραζινης - Google Patents

Πολυμορφικες μορφες της υδροχλωρικης 1-[4-(5-κυανοϊνδολ-3-υλ) βουτυλ]-4-(2-καρβαμοϋλβενζοφουραν-5-υλ)πιπεραζινης

Info

Publication number
CY1109447T1
CY1109447T1 CY20091101023T CY091101023T CY1109447T1 CY 1109447 T1 CY1109447 T1 CY 1109447T1 CY 20091101023 T CY20091101023 T CY 20091101023T CY 091101023 T CY091101023 T CY 091101023T CY 1109447 T1 CY1109447 T1 CY 1109447T1
Authority
CY
Cyprus
Prior art keywords
disorders
cyanoindol
butyl
piperazine
hydrochloride
Prior art date
Application number
CY20091101023T
Other languages
English (en)
Inventor
Andreas Bathe
Bernd Helfert
Steffen Neunfeld
Heike Kniel
Matthias Bartels
Susanne Rudolph
Henning Böttcher
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8177643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1109447(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of CY1109447T1 publication Critical patent/CY1109447T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

Η εφεύρεση αναφέρεται σε νέες κρυσταλλικές παραλλαγές του υδροχλωριδίου της 1-[4-(5-κυανοϊνδολ -3-υλ) βουτυλ]-4- (2-καρβαμόυλ- βενζοφουραν -5-υλ) -πιπεραζίνης, στην κρυσταλλική παραλλαγή του διυδροχλωριδίου της 1-[4-(5-κυανοϊνδολ -3-υλ) βουτυλ]-4- (2-καρβαμόυλ- βενζοφουραν-5-υλ) -πιπεραζίνης και της άμορφης υδροχλωρικής 1-[4-(5-κυανοϊνδολ -3-υλ) βουτυλ]-4- (2-καρβαμόυλ- βενζοφουραν -5-υλ) -πιπεραζίνης, οι οποίες είναι κατάλληλες για την παρασκευή στερεών φαρμάκων για τη θεραπεία ή την πρόληψη των καταθλιπτικών διαταραχών, διαταραχών άγχους, διπολικών διαταραχών, μανίας, άνοιας, διαταραχών που σχετίζονται με την ουσία, σεξουαλικών δυσλειτουργιών, διαταραχών σίτισης, παχυσαρκίας, ινομυαλγίας, διαταραχών ύπνου, ψυχιατρικών διαταραχών, εγκεφαλικού εμφράγματος, ψυχολογικής υπερέντασης, για τη θεραπεία των παρενεργειών κατά τη θεραπεία της υπέρτασης, των εγκεφαλικών ανωμαλιών, του χρόνιου πόνου, της ακρομεγαλίας, του υπογοναδισμού, της δευτεροπαθούς αμηνόρροιας, του προ-εμμηνορυσιακού συνδρόμου και της ανεπιθύμητης επιλόχειας γαλουχίας.
CY20091101023T 2001-06-19 2009-09-30 Πολυμορφικες μορφες της υδροχλωρικης 1-[4-(5-κυανοϊνδολ-3-υλ) βουτυλ]-4-(2-καρβαμοϋλβενζοφουραν-5-υλ)πιπεραζινης CY1109447T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01113647 2001-06-19
EP02754627A EP1397357B9 (en) 2001-06-19 2002-06-05 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride

Publications (1)

Publication Number Publication Date
CY1109447T1 true CY1109447T1 (el) 2014-08-13

Family

ID=8177643

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091101023T CY1109447T1 (el) 2001-06-19 2009-09-30 Πολυμορφικες μορφες της υδροχλωρικης 1-[4-(5-κυανοϊνδολ-3-υλ) βουτυλ]-4-(2-καρβαμοϋλβενζοφουραν-5-υλ)πιπεραζινης

Country Status (30)

Country Link
US (15) US7381726B2 (el)
EP (1) EP1397357B9 (el)
JP (3) JP4624667B2 (el)
KR (1) KR20040012922A (el)
CN (2) CN101139345B (el)
AR (1) AR034595A1 (el)
AT (1) ATE437871T1 (el)
AU (1) AU2002320822B2 (el)
BR (1) BR0210495A (el)
CA (16) CA2782628A1 (el)
CY (1) CY1109447T1 (el)
CZ (2) CZ305220B6 (el)
DE (1) DE60233133D1 (el)
DK (1) DK1397357T3 (el)
EC (1) ECSP044943A (el)
EE (1) EE05454B1 (el)
ES (1) ES2330314T3 (el)
HK (2) HK1066003A1 (el)
HU (1) HU229601B1 (el)
IL (2) IL159426A0 (el)
MX (1) MXPA03011723A (el)
MY (1) MY151087A (el)
NZ (1) NZ530642A (el)
PL (1) PL208708B1 (el)
PT (1) PT1397357E (el)
RU (1) RU2303598C2 (el)
SK (2) SK288162B6 (el)
UA (1) UA76758C2 (el)
WO (1) WO2002102794A2 (el)
ZA (1) ZA200400329B (el)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA76758C2 (uk) 2001-06-19 2006-09-15 Мерк Патент Гмбх Поліморфні форми гідрохлориду 1-'4-(5-ціаноіндол-3-іл)бутил-4-(2-карбамоїлбензофуран-5-іл)піперазину
DE10259244A1 (de) * 2002-12-17 2004-07-01 Merck Patent Gmbh N-(Indolethyl-)cycloamin-Verbindungen
DE10326939A1 (de) * 2003-06-16 2005-01-05 Merck Patent Gmbh Indol-Derivate
DE10326940A1 (de) * 2003-06-16 2005-01-05 Merck Patent Gmbh Indol-Derivate
WO2012131706A1 (en) * 2011-03-20 2012-10-04 Cadila Healthcare Limited Amorphous form of vilazodone hydrochloride and process for its preparation
CN102219783B (zh) * 2011-05-05 2013-07-03 天津市汉康医药生物技术有限公司 盐酸维拉佐酮及其组合物
US9505744B2 (en) 2011-11-23 2016-11-29 Assia Chemical Industries Ltd. Solid state forms of vilazodone and vilazodone hydrochloride
EP2791131A1 (en) 2011-12-12 2014-10-22 Ranbaxy Laboratories Limited Amorphous vilazodone hydrochloride, a process for its preparation and pharmaceutical compositions thereof
US9969721B2 (en) 2012-04-12 2018-05-15 Alembic Pharmaceuticals Limited Process for the preparation of vilazodone hydrochloride and its amorphous form
EP2838894A1 (en) * 2012-04-16 2015-02-25 Ranbaxy Laboratories Limited Process for the preparation of crystalline vilazodone hydrochloride
WO2013164794A1 (en) 2012-05-04 2013-11-07 Ranbaxy Laboratories Limited Crystalline forms of vilazodone hydrochloride
US20150126525A1 (en) 2012-05-11 2015-05-07 Dr. Reddy's Laboratories Limited Crystalline forms of vilazodone hydrochloride and vilazodone free base
WO2013175361A1 (en) 2012-05-24 2013-11-28 Ranbaxy Laboratories Limited Process for the preparation of vilazodone hydrochloride
CN102702180A (zh) * 2012-05-25 2012-10-03 吉林三善恩科技开发有限公司 一种维拉佐酮有机药物共晶及其制备方法
US8835635B2 (en) * 2012-06-05 2014-09-16 Symed Labs Limited Amorphous form of vilazodone hydrochloride substantially free of crystalline forms
WO2013182946A2 (en) 2012-06-06 2013-12-12 Ranbaxy Laboratories Limited Process for the preparation of vilazodone hydrochloride
US9382233B2 (en) 2012-06-13 2016-07-05 Apotex Inc. Forms of vilazodone and processes for the preparation thereof
WO2014028473A1 (en) 2012-08-13 2014-02-20 Assia Chemical Industries Ltd. New salts of vilazodone and solid state forms thereof
WO2014049609A2 (en) * 2012-09-26 2014-04-03 Cadila Healthcare Limited Novel salts of vilazodone
WO2014049612A2 (en) * 2012-09-27 2014-04-03 Msn Laboratories Limited Processes and polymorphs of 5-[4-[4-(5-cyano-1h-indol-3-yl) butyl]-1-piperazinyl]-2-benzofuran carboxamide and its salts
WO2014064715A2 (en) 2012-10-22 2014-05-01 Cadila Healthcare Limited Amorphous form of vilazodone hydrochloride and process for preparing thereof
CN103772367B (zh) * 2012-10-24 2016-05-25 杭州和泽医药科技有限公司 盐酸维拉佐酮v晶型的制备方法及其应用
CN103772368B (zh) * 2012-10-24 2016-08-03 杭州和泽医药科技有限公司 盐酸维拉佐酮iv晶型的制备方法及其应用
WO2014087428A1 (en) * 2012-12-07 2014-06-12 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for preparation of vilazodone and intermediates thereof
CN102977083A (zh) * 2012-12-17 2013-03-20 南京海纳医药科技有限公司 1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨甲酰-苯并呋喃-5-基)-哌嗪盐酸盐的新晶型xⅶ及其制备方法
WO2014178013A1 (en) 2013-04-30 2014-11-06 Ranbaxy Laboratories Limited Vilazodone impurities, process for their preparation, and their use as reference standards
IN2013MU02001A (el) 2013-06-12 2015-05-29 Lupin Ltd
EP2824104A1 (en) 2013-07-12 2015-01-14 Sandoz AG Process for the preparation of form III of Vilazodone hydrochloride
WO2015019256A1 (en) 2013-08-06 2015-02-12 Ranbaxy Laboratories Limited Pharmaceutical composition of vilazodone and processes of preparation thereof
WO2015019237A1 (en) 2013-08-06 2015-02-12 Ranbaxy Laboratories Limited Pharmaceutical composition of vilazodone
WO2015037010A1 (en) * 2013-09-13 2015-03-19 Symed Labs Limited Preparation of vilazodone hydrochloride crystalline form iv
CN104610238A (zh) * 2013-11-01 2015-05-13 北京英科博雅科技有限公司 一种维拉佐酮盐酸盐iii晶型新的制备方法
ITMI20131839A1 (it) * 2013-11-06 2015-05-07 Dipharma Francis Srl Co-cristallo di un farmaco antidepressivo
WO2015102019A2 (en) * 2013-12-30 2015-07-09 Msn Laboratories Private Limited Process for the preparation of polymorphs of 5-[4-[4-(5-cyano-1h-indol-3-yl)butyl]-1-piperazinyl]-2-benzofuran carboxamide hydrochloride
CN105017233A (zh) * 2014-04-23 2015-11-04 天津药物研究院 一种盐酸维拉佐酮晶体、其制备方法、药物组合物和用途
CN105820157B (zh) * 2015-01-09 2021-05-25 石药集团中奇制药技术（石家庄）有限公司 一种盐酸维拉佐酮晶型及其制备方法
CN106518854A (zh) * 2016-09-21 2017-03-22 北京万全德众医药生物技术有限公司 一种盐酸维拉佐酮晶型ⅳ的制备方法
TR201702103A2 (tr) 2017-02-13 2018-08-27 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vilazodon hi̇droklorürün tablet formlari
TR201702104A2 (tr) 2017-02-13 2018-08-27 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vi̇lazodon hi̇droklorür farmasöti̇k bi̇leşi̇mleri̇
CN107098889A (zh) * 2017-03-17 2017-08-29 北京万全德众医药生物技术有限公司 盐酸维拉佐酮药物晶型ⅲ的制备方法
CN109503560A (zh) * 2017-09-14 2019-03-22 北京万全德众医药生物技术有限公司 盐酸维拉佐酮ⅺ晶型的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US532241A (en) * 1895-01-08 Computing-machine
US1294526A (en) * 1917-09-21 1919-02-18 Gerhard Nicolaas Vis Manufacture of sodium carbonate and ammonium sulfate from bisulfate of soda.
DE4333254A1 (de) * 1993-09-30 1995-04-06 Merck Patent Gmbh Piperidine und Piperazine
US5521241A (en) * 1994-08-30 1996-05-28 W. R. Grace & Co.-Conn. Styrene copolymer-based plastisol containing glycidyl methacrylate
DE19514567A1 (de) * 1995-04-20 1996-10-24 Merck Patent Gmbh Benzofurane
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
CA2415876A1 (en) 2000-07-13 2002-01-24 Hydrogen Energy America Llc Method and apparatus for controlled generation of hydrogen by dissociation of water
UA76758C2 (uk) * 2001-06-19 2006-09-15 Мерк Патент Гмбх Поліморфні форми гідрохлориду 1-'4-(5-ціаноіндол-3-іл)бутил-4-(2-карбамоїлбензофуран-5-іл)піперазину
US7384020B2 (en) * 2006-06-30 2008-06-10 Amtek System Co., Ltd. Supporting frame structure

Also Published As

Publication number Publication date
CA2782868A1 (en) 2002-12-27
CA2683040C (en) 2012-09-25
SK288162B6 (sk) 2014-03-04
AU2002320822B2 (en) 2007-11-15
US20140275115A1 (en) 2014-09-18
JP5411734B2 (ja) 2014-02-12
JP2010132688A (ja) 2010-06-17
IL159426A0 (en) 2004-06-01
RU2303598C2 (ru) 2007-07-27
UA76758C2 (uk) 2006-09-15
WO2002102794A2 (en) 2002-12-27
US7981894B2 (en) 2011-07-19
EE05454B1 (et) 2011-08-15
US8921375B2 (en) 2014-12-30
EP1397357A2 (en) 2004-03-17
US7834020B2 (en) 2010-11-16
PL208708B1 (pl) 2011-05-31
SK288334B6 (sk) 2016-02-02
JP4624667B2 (ja) 2011-02-02
US8236804B2 (en) 2012-08-07
WO2002102794A3 (en) 2003-02-20
CN100384841C (zh) 2008-04-30
ES2330314T3 (es) 2009-12-09
US20190343831A1 (en) 2019-11-14
ATE437871T1 (de) 2009-08-15
JP5714824B2 (ja) 2015-05-07
EE200400019A (et) 2004-04-15
US9624204B2 (en) 2017-04-18
US20170182037A1 (en) 2017-06-29
US20100016332A1 (en) 2010-01-21
CA2782515A1 (en) 2002-12-27
JP2010132687A (ja) 2010-06-17
US7381726B2 (en) 2008-06-03
MXPA03011723A (es) 2004-03-19
CA2451028A1 (en) 2002-12-27
CZ200426A3 (cs) 2004-04-14
US20110294824A1 (en) 2011-12-01
PT1397357E (pt) 2009-11-03
US20110183994A1 (en) 2011-07-28
US20110294825A1 (en) 2011-12-01
US20110312971A1 (en) 2011-12-22
US8318744B2 (en) 2012-11-27
CA2782628A1 (en) 2002-12-27
EP1397357B1 (en) 2009-07-29
US8673921B2 (en) 2014-03-18
NZ530642A (en) 2006-09-29
CA2782623A1 (en) 2002-12-27
BR0210495A (pt) 2004-08-17
CA2782761A1 (en) 2002-12-27
CA2782615A1 (en) 2002-12-27
CZ304471B6 (cs) 2014-05-21
MY151087A (en) 2014-04-15
ECSP044943A (es) 2004-02-26
US20110190317A1 (en) 2011-08-04
RU2004100824A (ru) 2005-06-20
SK162004A3 (en) 2004-04-06
JP2004534803A (ja) 2004-11-18
CA2782517A1 (en) 2002-12-27
CN1516699A (zh) 2004-07-28
US8193195B2 (en) 2012-06-05
CA2451028C (en) 2012-07-17
CA2782865A1 (en) 2002-12-27
CA2782862A1 (en) 2002-12-27
PL364576A1 (en) 2004-12-13
CA2782521A1 (en) 2002-12-27
US20140024658A1 (en) 2014-01-23
IL159426A (en) 2011-12-29
DK1397357T3 (da) 2009-10-05
CA2782857A1 (en) 2002-12-27
CN101139345B (zh) 2012-07-11
HK1066003A1 (en) 2005-03-11
CZ305220B6 (cs) 2015-06-17
CA2683040A1 (en) 2002-12-27
HUP0400236A3 (en) 2010-06-28
US20150080411A1 (en) 2015-03-19
US20040147528A1 (en) 2004-07-29
DE60233133D1 (de) 2009-09-10
CA2782791A1 (en) 2002-12-27
CA2782519A1 (en) 2002-12-27
US20090023749A1 (en) 2009-01-22
CN101139345A (zh) 2008-03-12
US20210251986A1 (en) 2021-08-19
CA2782494A1 (en) 2002-12-27
AR034595A1 (es) 2004-03-03
ZA200400329B (en) 2005-06-29
HUP0400236A2 (hu) 2004-06-28
US20130102616A1 (en) 2013-04-25
HK1116165A1 (el) 2008-12-19
KR20040012922A (ko) 2004-02-11
HU229601B1 (en) 2014-02-28
US8927552B2 (en) 2015-01-06
EP1397357B9 (en) 2009-11-18

Similar Documents

Publication Publication Date Title
CY1109447T1 (el) Πολυμορφικες μορφες της υδροχλωρικης 1-[4-(5-κυανοϊνδολ-3-υλ) βουτυλ]-4-(2-καρβαμοϋλβενζοφουραν-5-υλ)πιπεραζινης
NO20061562L (no) Anvendelse av 1- [4-(5-cyanindol-3yl)butyl ] -4-(2-karbamoylbenzofuran-5-yl)-piperazin og dets fysiologisk akseptable salter
MY132566A (en) Benzimidazolone histamine h3 antagonists
ATE531369T1 (de) Polymorphe formen von 3-(4-amino-1-oxo-1,3- dihydro-isoindol-2-yl)-piperidin-2,6-dion
DE112004000927A5 (de) Benetzbarer Tantal-Kondensator, verwendbar ohne Reformation und medizinische Vorrichtung zur Verwendung damit
GR3030253T3 (en) Novel substituted piperidines useful for the treatment of allergic diseases
NO20055256D0 (no) 4-(4-heterosyklylalkoksy)fenyl)-1-(heterosyklyl-karbonyl)piperidinderivater og beslektede forbindelser som histamin H3-antagonister for behandling av neurologiske sykdommer som Alzheimers
TNSN04088A1 (en) 3, 4-disubstituted, 3, 5-disubstituted and 3, 4, 5-substituted piperidines and piperazines
TW200607497A (en) Non-imidazole tertiary amines as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other cns disorders
DE60300021D1 (de) (S)-4-Amino-5-Chloro-2-Methoxy-N-[1-[1-(2-Tetrahydrofuryl-Carbonyl)-4-Piperidinylmethyl]-4-Piperidinyl]benzamid zur Behandlung von Magen-Darmbewegungskrankheiten
GT200000034A (es) Compuestos y procedimientos para el tratamiento de asma, alergia y trastornos inflamatorios.
ATE303379T1 (de) 4-(phenyl-piperidin-4-ylidenmethyl)-benzamid- derivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen
DE60307289D1 (de) Spirosubstituierte piperidine als selektive antagonisten des melanin konzentrierenden hormon rezeptors für die behandlung von fettleibigkeit
ATE390134T1 (de) (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4- fluorophenyl)ethyl)-4-piperidinemethanol oder prodrug davon zur behandlung von demenzsymptomen oder kognitiven störungen
DE60200135D1 (de) 4-(2-Pyridyl)piperazine als Agonisten des 5HT7 Rezeptors
ATE468855T1 (de) Kombination von stickstoff-senf analogen und imatinib für die behandlung von chronischer lymphatischer leukämie
DK1420788T3 (da) Nye piperidin-2,6-dion-bisulfatsalte og deres anvendelse til behandling af stressrelaterede emotionelle lidelser
ATE323094T1 (de) Antidepressiv wirkende cycloalkylaminderivate von mit heterocyclen kondensierten benzodioxanen
ATE287400T1 (de) 4-(phenylpiperidin-4-ylidenmethyl) benzamidderivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen
GB0219639D0 (en) Novel piperidin-2,6-dione salts and their use for the treatment of stress-related affective disorders
ATE313529T1 (de) 4-(phenyl(piperidin-4-yl)amino) benzamidderivate und deren verwendung zur behandlung von schmerzen,angst oder gastrointestinalen störungen
EA200300537A1 (ru) Антагонисты гистаминовых рецепторов
NO20070884L (no) Dimere forbindelser av piperidin, piperazin eller morfolin eller deres 7-leddede analoger egnet for behandlingen av nevrodegenerative lidelser
ATE348614T1 (de) 2-(4-(phenylamino)-piperidin-1-yl)-n-phenyl- acetamid derivate und verwandte verbindungen als neuropeptid y5 (npy5) liganden zur behandlung von fettleibigkeit
TH57869B (th) การใช้ในทางใหม่ของ 1-[4-(5-ไซยาโนอินดอล-3-อิล)บิวทิล]-4-(2-คาร์บาโมอิลเบนโซฟูแรน-5-อิล)พิเพอราซีน และเกลือของสารดังกล่าวซึ่งเป็นที่ยอมรับทางสรีรวิทยา